Drug Profile
Pimitespib - Taiho Pharmaceutical
Alternative Names: Jeselhy; TAS 116Latest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Benzamides; Imidazoles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours
- Phase II Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 08 Nov 2023 Phase-II clinical trials in Prostate cancer in Japan after June 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 20 Oct 2023 Efficacy and adverse events data from a phase I CHAPTER-GIST-101 trial in Gastrointestinal stromal tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 30 Aug 2022 Launched for Gastrointestinal stromal tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO)